ErSO-DFP

• Description :

  ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO (HY-132247) . ErSO-DFP displays antitumor activity against MCF-7 in mice. ErSO-DFP can cross the blood brain barrier[1].

• UNSPSC :

  12352005

• Target :

  Estrogen Receptor/ERR

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/erso-dfp.html

• Purity :

  99.56

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C1NC2=C(C=CC=C2[C@]1(N3CCC(F)(CC3)F)C4=CC=C(C=C4)O)C(F)(F)F

• Molecular Formula :

  C20H17F5N2O2

• Molecular Weight :

  412.35

• References & Citations :

  [1]Matthew W Boudreau, et al. Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. J Med Chem. 2022 Mar 10;65 (5) :3894-3912.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2768139-76-8]